Treatment of Lichen Planopilaris With Abrocitinib
February 2025
in “
International Journal of Dermatology
”
New to Minoxidil? There is a guide in the encyclopedia. Read the guide → Studysummary This case report by the researchers observed a complete remission of lichen planopilaris in a 58-year-old woman after treatment with the JAK-1 inhibitor abrocitinib, although they noted that concurrent topical therapy might have contributed to this outcome. Our plain-language summary of this paper — not a Tressless recommendation.
This case study reports the first instance of complete remission of Lichen Planopilaris (LPP) in a 58-year-old woman following treatment with abrocitinib, a selective JAK-1 inhibitor. The patient, who had a history of allergic asthma, rhinitis, and atopic dermatitis, showed significant improvement in LPP symptoms after switching from tralokinumab to abrocitinib, alongside topical clobetasol propionate and minoxidil. At the 3-month follow-up, the patient experienced no scalp pruritus or burning, and her LPP Activity Index (LPPAI) score dropped to 0, indicating remission. The study suggests that abrocitinib could be a promising treatment for LPP, although further research is needed to fully understand the therapeutic potential of JAK inhibitors in managing LPP and similar inflammatory conditions. No adverse events were reported during the treatment period.
